Ascendis Reports Positive Week 52 Infant Data for TransCon CNP in Achondroplasia
ASND sits 40% above its 52-week low of $186.054.
Summary
Ascendis Pharma reported positive Week 52 sentinel cohort data from the reACHin Trial showing TransCon CNP stabilized or improved foramen magnum stenosis and supported linear growth in infants with achondroplasia, with no decompression surgeries and a clean safety profile.
Key Events · Product Development and Regulatory · ASND
-
Week 52 Infant Data Positive
TransCon CNP stabilized or improved foramen magnum stenosis in all seven infants in the reACHin Trial sentinel cohort, with mean sagittal diameter increase of +3.15 mm and no decompression surgeries over 52 weeks.
-
Linear Growth Benefit
Mean change in ACH-specific supine length Z-score was +0.42 and mean annualized growth velocity was 9.9 cm/year, supporting efficacy in infants aged 0 to <2 years.
-
Clean Safety Profile
No injection site reactions, no deaths, fractures, bone-related events, or symptomatic hypotension; no treatment-related AEs or discontinuations over 52 weeks.
-
Regulatory and Commercial Expansion
Data support potential label expansion for TransCon CNP into infants, building on positive Week 104 data in older children reported June 30, 2026.
Analysis · ASND · Life Sciences
Ascendis Pharma disclosed Week 52 data from the open-label sentinel cohort of its pivotal reACHin Trial, showing TransCon CNP stabilized or improved foramen magnum stenosis and supported linear growth in infants with achondroplasia aged 0 to <2 years. The data address a serious complication — skull base narrowing that can compress the brain stem and spinal cord — and showed no decompression surgeries were needed over 52 weeks. This expands the potential label for TransCon CNP into the infant population, a key commercial and regulatory opportunity, and follows positive Week 104 data in older children reported in June 2026.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASND was trading at $260.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3B. The 52-week trading range was $186.05 to $282.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.